Abstract
BACKGROUND The clinical onset serial interval, or the time between the onset of symptoms in successive cases in a chain of infection, is often used as a measurable proxy for the transmission serial interval of an infectious disease. Current estimates of the mean clinical onset serial interval of COVID-19 range from 3.96 to 7.5 days. In this article, we define the diagnostic serial interval as the time between the diagnosis dates of the infector and infectee. We study and compare the clinical onset and diagnostic serial intervals of SARS-CoV-2/COVID-19 in South Korea.
METHODS Analyzing the DS4C project data which summarize information on SARS-CoV-2/COVID-19 cases reported by regional governments in South Korea, we estimate the means of the clinical onset serial interval, the diagnostic serial interval and the difference between the two. We use the balanced cluster bootstrap method to construct 95% bootstrap confidence intervals.
RESULTS The mean clinical onset serial interval and mean diagnostic serial interval were estimated to be 3.58 days (95% CI: 2.62, 4.53) and 3.68 days (95% CI: 3.14, 4.22), respectively. A matched sample analysis showed that the diagnostic serial interval was significantly shorter than the clinical onset serial interval (estimated mean difference −1.17 days, 95% CI: −2.26, −0.09).
CONCLUSIONS The short diagnostic serial interval of SARS-CoV-2/COVID-19 in South Korea may explain why South Korea was able to contain the COVID-19 outbreak and avoid high mortality. We conjecture that the mean diagnostic serial interval may serve as a predictor for the success of a country’s containment efforts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We declare no funding sources for writing this manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Our research is based on the publicly accessible DS4C project data.
